Long interval between HCV infection and development of hepatocellular carcinoma

Wiley - Tập 15 Số 3 - Trang 159-163 - 1995
Lluı́s Castells1, Vı́ctor Vargas1, Antonio González1, Juan Ignacio Esteban1, Rafael Esteban1, J. Guardia1
1Liver Unit, Hospital General Universitari Vall d'Hebron, Universitat Autonoma, Barcelona, Spain.

Tóm tắt

Abstract: A high prevalence of HCV infection has been reported in patients with hepatocellular carcinoma. The progression from acute transfusion‐associated hepatitis to hepatic cirrhosis and hepatocellular carcinoma has been suggested in several studies to be very long. We have investigated the prevalence of anti‐HCV and the interval between HCV infection and hepatocellular carcinoma among 191 consecutive patients with cirrhosis and liver‐cell carcinoma. Serum samples from 191 patients with cirrhosis and hepatocellular carcinoma, consecutively diagnosed in our hospital between 1988 and 1993, were tested for serological markers of HBV and HCV infection. One hundred and forty‐eight patients (77.5%; 95% confidence interval (c.i): 76% to 80%) were anti‐HCV positive by 2nd generation enzyme immunoassay (confirmed by 2nd generation recombinant immunoblot assay) and 152 patients (79.5%; 95% c.i: 76% to 80%) were anti‐HCV positive by 3rd generation enzyme immunoassay, while only 14 (7.4%; 95% c.i: 5% to 10%) were HBsAg positive. Of the 29 anti‐HCV positive patients with previous transfusion, the interval between the date of blood transfusion and the diagnosis of hepatic cirrhosis was 24±12.5 years and that of hepatocellular carcinoma was 26.8±12.4 years. These results confirm the high prevalence of HCV infection in patients with hepatocellular carcinoma and the slow sequential progression from HCV infection through cirrhosis and hepatocellular carcinoma.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(81)90585-7

Beasley R P., 1982, Hepatitis B virus as the etiologic agent in hepatocellular carcinoma. Epidemiologic considerations, Hepatology, 2, 21s

10.1056/NEJM198206103062302

10.1002/hep.1840120321

10.1007/BF01317042

Dienstag J L., 1983, Non‐A, non‐B hepatitis. I. Recognition, epidemiology, and clinical features, Gastroenterology, 85, 439, 10.1016/0016-5085(83)90336-0

10.7326/0003-4819-101-6-794

Sakamoto M., 1988, Increasing incidence of hepatocellular carcinoma possibly associated with non‐A, non‐B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgical resected cases, Cancer Res, 48, 7294

10.1126/science.2496467

10.1016/S0140-6736(89)91015-5

10.1016/S0140-6736(89)91016-7

10.7326/0003-4819-116-2-97

Castells LI, 1993, Carcinoma hepatocellular: clinica, diagnóstico y supervivencia en 140 casos, Med Clin (Barc), 100, 441

10.1016/0168-8278(92)90156-J

10.1002/hep.1840120409

10.1002/hep.1840120323

10.1002/1097-0142(19920115)69:2<342::AID-CNCR2820690211>3.0.CO;2-T

Esteban J I, 1992, Progress in liver diseases, 253

10.1056/NEJM199212313272703

Bosch F X, 1991, Etiology, pathology and treatment of hepatocellular carcinoma in North America, 35

10.1016/0016-5085(92)91523-7

Thông tin
Thông tin xuất bản

Wiley

Tập 15 Số 3

159-163

Thông tin tác giả